Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP4K2A | P48426 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 5/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12596599 | 0.97 | PIP4K2A (0.46) | PIP4K2AGPR119CYP3A4CYP2C9EGFR | |
| SCHEMBL12596557 | 0.89 | CYP3A4 (0.49) | PIP4K2AGPR119CYP3A4CYP2C9EGFR | |
| SCHEMBL12596555 | 0.87 | PIP4K2A (0.46) | PIP4K2AGPR119CYP3A4CYP2C9EGFR | |
| SCHEMBL12596610 | 0.87 | PIP4K2A (0.44) | PIP4K2AGPR119CYP3A4CYP2C9EGFR | |
| SCHEMBL12596526 | 0.87 | GPR119 (0.59) | PIP4K2AGPR119 | |
| SCHEMBL12596617 | 0.85 | PIP4K2A (0.42) | PIP4K2AGPR119CYP3A4CYP2C9EGFR | |
| SCHEMBL12596520 | 0.83 | GPR119 (0.58) | PIP4K2AGPR119 | |
| SCHEMBL12596559 | 0.82 | PIP4K2A (0.44) | PIP4K2AGPR119CYP3A4CYP2C9EGFR | |
| SCHEMBL12395352 | 0.79 | GPR119 (0.48) | PIP4K2AGPR119CYP3A4CYP2C9 | |
| SCHEMBL12596597 | 0.78 | PIP4K2A (0.50) | PIP4K2AEGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118286-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS GPCR MODULATORS | SCHERING CORPORATION | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118286-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS GPCR MODULATORS | GPR119, GCGR, GPR35 | PIP4K2A 2352/4885GPR119 1/4885CYP3A4 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.